The importance of addressing multiple risk markers in type 2 diabetes: Results from the LEADER and SUSTAIN 6 trials

• DOI: 10.1111/dom.14578
• Publication Date: 2021-10-22T03:37:07Z
• Authors: Emilie H. Zobel; Bernt Johan von S...; Tine W. Hansen; Frederik Persson; Søren Rasmussen; Benjamin Wolthers; Peter Rossing
• Keywords: Mace; Glycated hemoglobin

To investigate to what extent multiple risk marker improvements confer lower of cardiovascular and kidney complications in a contemporary type 2 diabetes population.Post-hoc analysis the LEADER (n = 8638; median follow-up 3.8 years) SUSTAIN 6 3040; 2.1 outcome trials. Participants were those with baseline year-1 assessment at least one parameters interest; we pooled liraglutide-/semaglutide- placebo-treated groups categorized them by number markers clinically relevant after 1 year study participation. We investigated major adverse events (MACE), expanded MACE, death nephropathy. Predefined changes: body weight loss ≥5%; reductions in: glycated haemoglobin ≥1%, systolic blood pressure ≥5 mmHg low-density lipoprotein cholesterol ≥0.5 mmol/L; estimated glomerular filtration rate change ≥0 ml/min/1.73 m2 urinary albumin-to-creatinine ratio ≥30% value. Cox regression analysed outcomes adjusted for levels treatment group stratified trial.Participants two, three, or four more improved versus participants no improvement had reduced MACE [hazard (95% confidence interval) 0.80 (0.67-0.96); (0.66-0.97); 0.82 (0.66-1.02)], [0.66 (0.45-0.96), 0.67 (0.45-0.99), 0.60 (0.38-0.94)] nephropathy [0.71 (0.52-0.97), 0.48 (0.34-0.68), 0.43 (0.29-0.65)].In persons diabetes, ≥2 conferred reduction none marker. The decreased markers. These findings stress importance multifactorial interventions targeting all